FDA Grants RMAT Designation to ALLO-715 for Relapsed/Refractory Multiple Myeloma
April 21st 2021The FDA granted a Regenerative Medicine Advanced Therapy designation to the allogeneic chimeric antigen receptor T-cell therapy as a potential treatment for patients with relapsed/refractory multiple myeloma.
Orca-T Displays GVHD Prevention, Scalability Potential, and Tolerability in Hematologic Cancers
February 11th 2021Treatment with the first-generation precision cell therapy Orca-T led to a significant reduction in cases of graft-versus-host disease, an impressive GVHD relapse-free survival rate, a lack of treatment-related mortalities, while showcasing scalability potential.
Beti-Cel Results in Impressive Activity in Pediatric Transfusion-Dependent Beta-Thalassemia
February 10th 2021Treatment with the investigative gene cell therapy betibeglogene autotemcel led to durable transfusion independence in 87% of pediatric patients less than 18 years of age with transfusion-dependent beta-thalassemia with a median average hemoglobin of 11.3 g/dL.
Axi-Cel Active in Relapsed/Refractory B-Cell Lymphomas Irrespective of Chemo Sensitivity
February 9th 2021Responsiveness to treatment received immediately prior to CAR T-cell therapy may not be associated with post–CAR T outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma who receive axicabtagene ciloleucel.